AP864A - Treatment of the cns effects of HIV with VX-478, alone or in combination with azt or 3tc. - Google Patents

Treatment of the cns effects of HIV with VX-478, alone or in combination with azt or 3tc. Download PDF

Info

Publication number
AP864A
AP864A APAP/P/1998/001340A AP9801340A AP864A AP 864 A AP864 A AP 864A AP 9801340 A AP9801340 A AP 9801340A AP 864 A AP864 A AP 864A
Authority
AP
ARIPO
Prior art keywords
hiv
compound
formula
cns
azt
Prior art date
Application number
APAP/P/1998/001340A
Other languages
English (en)
Other versions
AP9801340A0 (en
Inventor
Pravin Ramsewak Chaturvedi
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AP9801340A0 publication Critical patent/AP9801340A0/xx
Application granted granted Critical
Publication of AP864A publication Critical patent/AP864A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
APAP/P/1998/001340A 1995-12-05 1996-12-05 Treatment of the cns effects of HIV with VX-478, alone or in combination with azt or 3tc. AP864A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/567,199 US5646180A (en) 1995-12-05 1995-12-05 Treatment of the CNS effects of HIV
PCT/US1996/019447 WO1997020554A1 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc

Publications (2)

Publication Number Publication Date
AP9801340A0 AP9801340A0 (en) 1998-09-30
AP864A true AP864A (en) 2000-08-11

Family

ID=24266147

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1998/001340A AP864A (en) 1995-12-05 1996-12-05 Treatment of the cns effects of HIV with VX-478, alone or in combination with azt or 3tc.

Country Status (23)

Country Link
US (1) US5646180A (no)
EP (1) EP0866696B1 (no)
JP (1) JP2000501713A (no)
KR (1) KR19990071750A (no)
CN (1) CN1203530A (no)
AP (1) AP864A (no)
AT (1) ATE279922T1 (no)
AU (1) AU722850B2 (no)
BR (1) BR9611861A (no)
CA (1) CA2238471A1 (no)
CZ (1) CZ291994B6 (no)
DE (1) DE69633680T2 (no)
ES (1) ES2231828T3 (no)
HU (1) HUP9903673A3 (no)
NO (1) NO317837B1 (no)
NZ (1) NZ324603A (no)
OA (1) OA10691A (no)
PL (1) PL187747B1 (no)
PT (1) PT866696E (no)
RU (1) RU2203658C2 (no)
UA (1) UA61902C2 (no)
WO (1) WO1997020554A1 (no)
ZA (1) ZA9610139B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
CZ429398A3 (cs) * 1996-06-25 1999-05-12 Glaxo Group Limited Kombinace účinných látek a farmaceutický prostředek
BR9709939A (pt) * 1996-06-25 1999-08-10 Glaxo Group Ltd Combinação formulação farmacêutica processo de tratamento de uma infecção por hiv em um animal infectado usos de éster tetraidro-3-furanila do ácido 3s[3r*(1r*,2s*)]-[-3-[[4-amino-fenil)sulfonil](2-metilprop ril)-amino]-2-hidroxi-1-fenilmetil)propil]-carbâmico de zidovudina e de (2r,cis)-4-amino-1-(2-hidroximetil-1,3-oxatiolan-5-il)-(1h)-pirimidin-2-ona e pacote para paciente
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
JP2001525840A (ja) * 1997-05-17 2001-12-11 グラクソ、グループ、リミテッド 炭素環式ヌクレオシド１５９２ｕ８９を含有する抗ウイルス的組合せ
AU8145198A (en) * 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
US6875773B1 (en) * 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
US20090197827A1 (en) * 1998-05-29 2009-08-06 Dunn Ben M Combination Therapy for Treatment of FIV Infection
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
EP1935380B1 (en) * 2000-10-16 2010-05-12 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
EP1427407A4 (en) 2001-03-23 2005-05-11 Luitpold Pharm Inc CONJUGATES BASED ON FATTY AMINES AND PHARMACEUTICAL AGENTS
ES2387562T3 (es) * 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
ES2363160T3 (es) 2004-07-27 2011-07-22 Gilead Sciences, Inc. Conjugados de fosfonato nucelosidico como agentes anti-vih.
AU2006206399B2 (en) * 2005-01-20 2012-04-05 University Of Rochester Compositions and methods relating to mitochondrial hyperpolarization in neurological disease
EP1976976A4 (en) * 2005-12-23 2010-12-15 Univ Rochester TREATMENT OF NEURO-AIDS WITH GLYCOGEN SYNTHASE KINASE (GSK) -3 INHIBITORS
PE20080191A1 (es) * 2006-04-19 2008-03-10 Abbott Gmbh & Co Kg Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6
TW201639852A (zh) 2008-12-09 2016-11-16 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
ES2819181T3 (es) 2014-02-28 2021-04-15 Attends Healthcare Products Inc Artículo absorbente con núcleo absorbente plegado de capa múltiple
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
MX2017000026A (es) 2014-07-11 2017-05-01 Gilead Sciences Inc Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
CA2997955A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
EP3801424A1 (en) 2018-05-28 2021-04-14 Attends Healthcare Products, Inc. Dryness layer laminate for absorbent articles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005639A1 (en) * 1992-09-08 1994-03-17 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of hiv-aspartyl protease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005639A1 (en) * 1992-09-08 1994-03-17 Vertex Pharmaceuticals Incorporated Sulfonamide inhibitors of hiv-aspartyl protease

Also Published As

Publication number Publication date
OA10691A (en) 2001-05-04
AU722850B2 (en) 2000-08-10
ES2231828T3 (es) 2005-05-16
NZ324603A (en) 2000-08-25
NO982556D0 (no) 1998-06-04
PL327061A1 (en) 1998-11-23
CA2238471A1 (en) 1997-06-12
UA61902C2 (en) 2003-12-15
ZA9610139B (en) 1997-06-17
PL187747B1 (pl) 2004-09-30
BR9611861A (pt) 1999-05-18
CZ170898A3 (cs) 1998-09-16
JP2000501713A (ja) 2000-02-15
HUP9903673A3 (en) 2000-08-28
NO317837B1 (no) 2004-12-20
CZ291994B6 (cs) 2003-07-16
RU2203658C2 (ru) 2003-05-10
NO982556L (no) 1998-06-04
EP0866696A1 (en) 1998-09-30
DE69633680T2 (de) 2006-02-23
DE69633680D1 (de) 2004-11-25
CN1203530A (zh) 1998-12-30
ATE279922T1 (de) 2004-11-15
AU1148697A (en) 1997-06-27
PT866696E (pt) 2005-03-31
KR19990071750A (ko) 1999-09-27
US5646180A (en) 1997-07-08
WO1997020554A1 (en) 1997-06-12
HUP9903673A2 (hu) 2000-03-28
AP9801340A0 (en) 1998-09-30
EP0866696B1 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
AP864A (en) Treatment of the cns effects of HIV with VX-478, alone or in combination with azt or 3tc.
AU706732B2 (en) THF-containing sulfonamide inhibitors of aspartyl protease
EP1136479B1 (en) Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
MXPA97008055A (en) Consistent aspartile protease inhibitors ensulfonamide containing oxygen heterocicle